tiprankstipranks
Advertisement
Advertisement

MNKD Stock Latest News

MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
Company AnnouncementsMannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
7h ago
MNKD
MannKind price target lowered to $8 from $10 at Mizuho
PremiumThe Fly
MannKind price target lowered to $8 from $10 at Mizuho
3d ago
MNKD
MannKind price target lowered to $6 from $7 at Truist
PremiumThe Fly
MannKind price target lowered to $6 from $7 at Truist
8d ago
MNKD
Theravance Biopharma price target raised to $17 from $14 at B. Riley
PremiumThe Fly
Theravance Biopharma price target raised to $17 from $14 at B. Riley
9d ago
MNKD
TBPH
MannKind price target lowered to $8 from $10 at Wedbush
PremiumThe Fly
MannKind price target lowered to $8 from $10 at Wedbush
1M ago
MNKD
UTHR
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
PremiumMarket NewsBiotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
2M ago
IBB
XBI
MannKind price target lowered to $7 from $8 at Wells Fargo
Premium
The Fly
MannKind price target lowered to $7 from $8 at Wells Fargo
2M ago
MNKD
MannKind price target lowered to $8 from $11 at H.C. Wainwright
Premium
The Fly
MannKind price target lowered to $8 from $11 at H.C. Wainwright
2M ago
MNKD
MannKind downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
MannKind downgraded to Sector Perform from Outperform at RBC Capital
2M ago
MNKD
UTHR
MannKind reports Q4 EPS (5c) vs 3c last year
PremiumThe Fly
MannKind reports Q4 EPS (5c) vs 3c last year
2M ago
MNKD
RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
PremiumThe Fly
RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
2M ago
MNKD
UTHR
Leerink sees MannKind selloff as ‘overreaction’ to headline news
PremiumThe Fly
Leerink sees MannKind selloff as ‘overreaction’ to headline news
2M ago
MNKD
UTHR
H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition
PremiumThe FlyH.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition
2M ago
MNKD
UTHR
United Therapeutics announces ‘category killer product’ Tresmi
Premium
The Fly
United Therapeutics announces ‘category killer product’ Tresmi
2M ago
MNKD
UTHR
MannKind sinks after United Therapeutics announces soft-mist inhaler
Premium
The Fly
MannKind sinks after United Therapeutics announces soft-mist inhaler
2M ago
MNKD
UTHR
Is MNKD a Buy, Before Earnings?
PremiumPre-Earnings
Is MNKD a Buy, Before Earnings?
2M ago
MNKD
MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential
PremiumRatings
MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential
2M ago
MNKD
MannKind says first patient enrolled in INHALE-1ST study of Afrezza
PremiumThe Fly
MannKind says first patient enrolled in INHALE-1ST study of Afrezza
2M ago
MNKD
Morning Movers: USA Rare Earth surges after government funding pact
PremiumThe Fly
Morning Movers: USA Rare Earth surges after government funding pact
3M ago
AAUC
CRWV
MannKind receives FDA approval for Afrezza dosage label
PremiumThe FlyMannKind receives FDA approval for Afrezza dosage label
3M ago
MNKD
MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch
Premium
Company Announcements
MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch
3M ago
MNKD
Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating
Premium
Ratings
Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating
3M ago
MNKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >